CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 83 enrolled
Drug / intervention
N-acetylcysteinedrug
Likely dose
N-acetylcysteine 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01501110
NCT01501110Phase 4Completed
CompareCT.gov

Evaluation of the Effects of N-acetylcysteine on Thyroid Hormone Levels in the Low T3 Syndrome

Federal University of Rio Grande do Sul·interventional·Posted Dec 29, 2011·Updated Mar 31, 2015

In Brief

A Phase 4 clinical trial evaluating N-acetylcysteine for Acute Myocardial Infarction and 2 related conditions. Completed, enrolled 83 participants across 2 sites.

Detailed Summary

The propose of this study is to determine whether N-acetylcysteine is effective in reversing the changes in thyroid hormones seen in critical illness, known as the low T3 syndrome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myocardial Infarction, Euthyroid Sick Syndrome, Ischemic Heart Disease
CountriesBrazil
CollaboratorsHospital de Clinicas de Porto Alegre, Programa de pós-graduação em endocrinologia

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 29, 2011
Enrollment StartNov 1, 2011
Primary CompletionJul 1, 2013
Study CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 14.5 years ago

Interventions

N-acetylcysteinedrug

in infusion of 1200 mg of n-acetylcysteine twice a day for 48 hours